Payment overview · 2025
General Payments
$807.09
29 reported records · 10 companies
Healthcare provider profile · identity verified
Gary G Chen, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · BROOKLYN, NY · NPI 1902978141
Verified facts
What the public records show
CMS Open Payments records show Gary G Chen, M.D. received $807.09 in general payments during 2025 across 29 reported records.
AstraZeneca Pharmaceuticals LP accounted for 30.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 15 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Trelegy Ellipta, Zenpep.
Aimmune Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ZENPEP as an associated drug or biological on 32144 records involving 12432 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Zenpep by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 64 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXIUM as an associated drug or biological on 464 records involving 299 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Nexium by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Jardiance by this doctor in 2024.
Gilead Sciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Vemlidy as an associated drug or biological on 782 records involving 554 distinct recipient NPIs. Public Medicare Part D data also shows 117 claims for Vemlidy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 81 claims for Trelegy Ellipta by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $244.74 | 30.3% | 13 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $150.00 | 18.6% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $125.00 | 15.5% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $65.47 | 8.1% | 3 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $63.09 | 7.8% | 3 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $58.87 | 7.3% | 2 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $51.01 | 6.3% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $19.89 | 2.5% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $14.68 | 1.8% | 1 | 2025 |
| SANOFI PASTEUR INC. | Unresolved — no canonical attribution shown | $14.34 | 1.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $807.09 | 29 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $150.00 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $118.79 | 6 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $86.47 | 5 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $63.09 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $59.68 | 3 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $51.01 | 3 | 2025 |
Source payment records
|
|||||
| BEXSERO Normalized: bexsero |
Biological | GlaxoSmithKline, LLC. | $48.09 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $19.89 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $19.89 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $17.38 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $14.68 | 1 | 2025 |
Source payment records
|
|||||
| FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE Normalized: flublok quadrivalent northern hemisphere |
Biological | SANOFI PASTEUR INC. | $14.34 | 1 | 2025 |
Source payment records
|
|||||
| FLUZONE HIGH-DOSE Normalized: fluzone high dose |
Biological | SANOFI PASTEUR INC. | $14.34 | 1 | 2025 |
Source payment records
|
|||||
| FLUZONE QUADRIVALENT NORTHERN HEMISPHERE Normalized: fluzone quadrivalent northern hemisphere |
Biological | SANOFI PASTEUR INC. | $14.34 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 64 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 81 | exact normalized | Medicare Part D |
| ZENPEP zenpep |
2025 | Zenpep | 2024 | 53 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Aimmune Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | ZENPEP open payments reported associated product |
CMS Open Payments — General Payments 32144 supporting records · 12432 recipient NPIs · example record 1249641927 |
Zenpep · 2024 Exact normalized brand match · 1 Part D row |
53 | 14 |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
64 | 11 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | NEXIUM open payments reported associated product |
CMS Open Payments — General Payments 464 supporting records · 299 recipient NPIs · example record 1206134180 |
Nexium · 2024 Exact normalized brand match · 1 Part D row |
53 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
54 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Gilead Sciences, Inc. Exact reporting entity; no affiliate inference |
2025 | Vemlidy open payments reported associated product |
CMS Open Payments — General Payments 782 supporting records · 554 recipient NPIs · example record 1234350906 |
Vemlidy · 2024 Exact normalized brand match · 1 Part D row |
117 | 11 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
21 | 19 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
81 | 21 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 2043 | 409 |
| Diclofenac Epolamine | Diclofenac Epolamine | 1845 | 225 |
| Vascepa | Icosapent Ethyl | 1674 | 238 |
| Losartan Potassium | Losartan Potassium | 1295 | 255 |
| Mometasone Furoate | Mometasone Furoate | 1258 | 157 |
| Amlodipine Besylate | Amlodipine Besylate | 913 | 186 |
| Metformin Hcl | Metformin Hcl | 872 | 177 |
| Bepotastine Besilate | Bepotastine Besilate | 869 | 112 |
| Baclofen | Baclofen | 865 | 192 |
| Clobetasol Emollient | Clobetasol Propionate/Emoll | 860 | 87 |
| Atenolol | Atenolol | 850 | 175 |
| Tamsulosin Hcl | Tamsulosin Hcl | 837 | 168 |
| Glimepiride | Glimepiride | 801 | 148 |
| Clopidogrel | Clopidogrel Bisulfate | 761 | 153 |
| Omeprazole | Omeprazole | 738 | 187 |
| Ammonium Lactate | Ammonium Lactate | 578 | 127 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 566 | 59 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 541 | 136 |
| Metoclopramide Hcl | Metoclopramide Hcl | 515 | 134 |
| Zolpidem Tartrate | Zolpidem Tartrate | 485 | 131 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 482 | 130 |
| Gabapentin | Gabapentin | 455 | 109 |
| Meclizine Hcl | Meclizine Hcl | 432 | 130 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 410 | 70 |
| Potassium Citrate Er | Potassium Citrate | 391 | 95 |
| Hydrocortisone | Hydrocortisone | 387 | 127 |
| Finasteride | Finasteride | 383 | 70 |
| Naproxen | Naproxen | 340 | 72 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 339 | 68 |
| Alendronate Sodium | Alendronate Sodium | 331 | 55 |
| Diclofenac Sodium | Diclofenac Sodium | 324 | 86 |
| Lidocaine | Lidocaine | 324 | 76 |
| Pioglitazone Hcl | Pioglitazone Hcl | 319 | 56 |
| Montelukast Sodium | Montelukast Sodium | 316 | 62 |
| Fluticasone Propionate | Fluticasone Propionate | 306 | 86 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 293 | 59 |
| Metoprolol Tartrate | Metoprolol Tartrate | 282 | 62 |
| Spironolactone | Spironolactone | 264 | 82 |
| Meloxicam | Meloxicam | 262 | 52 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 242 | 48 |
| Ibuprofen | Ibuprofen | 238 | 96 |
| Celecoxib | Celecoxib | 236 | 44 |
| Allopurinol | Allopurinol | 235 | 51 |
| Azithromycin | Azithromycin | 235 | 149 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 235 | 86 |
| Furosemide | Furosemide | 233 | 78 |
| Xarelto | Rivaroxaban | 231 | 42 |
| Memantine Hcl Er | Memantine Hcl | 230 | 57 |
| Clobetasol Propionate | Clobetasol Propionate | 226 | 54 |
| Ursodiol | Ursodiol | 226 | 55 |
| Azelastine Hcl | Azelastine Hcl | 224 | 65 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 224 | 48 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 221 | 42 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 208 | 45 |
| Ketoconazole | Ketoconazole | 199 | 50 |
| Famotidine | Famotidine | 194 | 68 |
| Halobetasol Propionate | Halobetasol Propionate | 194 | 42 |
| Pantoprazole Sodium | Pantoprazole Sodium | 193 | 45 |
| Synthroid | Levothyroxine Sodium | 190 | 41 |
| Nitroglycerin | Nitroglycerin | 182 | 50 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 178 | 136 |
| Metoprolol Succinate | Metoprolol Succinate | 172 | 37 |
| Simvastatin | Simvastatin | 168 | 31 |
| Pro Comfort Alcohol Pads | Alcohol Antiseptic Pads | 165 | 64 |
| Levothyroxine Sodium | Levothyroxine Sodium | 120 | 30 |
| Vemlidy | Tenofovir Alafenamide | 117 | 11 |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 115 | 25 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 108 | 27 |
| Metolazone | Metolazone | 108 | 43 |
| Fluocinonide | Fluocinonide | 104 | 21 |
| Digoxin | Digoxin | 99 | 23 |
| Memantine Hcl | Memantine Hcl | 98 | 24 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 98 | 26 |
| Procto-Med Hc | Hydrocortisone | 98 | 26 |
| Oxiconazole Nitrate | Oxiconazole Nitrate | 97 | 16 |
| Donepezil Hcl | Donepezil Hcl | 92 | 22 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 91 | 73 |
| Mirtazapine | Mirtazapine | 91 | 16 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 90 | 14 |
| Penicillin V Potassium | Penicillin V Potassium | 89 | 70 |
| Gemfibrozil | Gemfibrozil | 88 | 16 |
| Hydrochlorothiazide | Hydrochlorothiazide | 88 | 24 |
| Lidocaine-Prilocaine | Lidocaine/Prilocaine | 87 | 28 |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 84 | 30 |
| Amoxicillin | Amoxicillin | 83 | 55 |
| Dicyclomine Hcl | Dicyclomine Hcl | 81 | 42 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 81 | 21 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 80 | 21 |
| Irbesartan | Irbesartan | 78 | 17 |
| Myrbetriq | Mirabegron | 74 | 11 |
| Icosapent Ethyl | Icosapent Ethyl | 72 | 46 |
| Risedronate Sodium | Risedronate Sodium | 70 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 69 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 66 | 14 |
| Farxiga | Dapagliflozin Propanediol | 64 | 11 |
| Restasis | Cyclosporine | 64 | 11 |
| Cilostazol | Cilostazol | 63 | 12 |
| Colchicine | Colchicine | 63 | 16 |
| Tenofovir Disoproxil Fumarate | Tenofovir Disoproxil Fumarate | 63 | 11 |
| Clotrimazole | Clotrimazole | 61 | 14 |
| Eliquis | Apixaban | 61 | 12 |
| Mupirocin | Mupirocin | 61 | 17 |
| Loperamide | Loperamide Hcl | 59 | 37 |
| Alcohol Swabs | Alcohol Antiseptic Pads | 58 | 19 |
| Raloxifene Hcl | Raloxifene Hcl | 58 | 13 |
| Tacrolimus | Tacrolimus | 58 | 12 |
| Dexlansoprazole Dr | Dexlansoprazole | 55 | 13 |
| Symbicort | Budesonide/Formoterol Fumarate | 54 | suppressed |
| Nexium | Esomeprazole Magnesium | 53 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 53 | 14 |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 52 | 11 |
| Januvia | Sitagliptin Phosphate | 52 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 50 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 50 | 11 |
| Ciclopirox | Ciclopirox | 48 | 15 |
| True Comfort Safety Pen Needle | Pen Needle, Diabetic, Safety | 48 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 47 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 45 | 30 |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 45 | 15 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 44 | 16 |
| Timolol Maleate | Timolol Maleate | 44 | suppressed |
| Folic Acid | Folic Acid | 42 | 13 |
| Quetiapine Fumarate | Quetiapine Fumarate | 42 | suppressed |
| Clonazepam | Clonazepam | 41 | 13 |
| Escitalopram Oxalate | Escitalopram Oxalate | 41 | suppressed |
| Omeprazole-Sodium Bicarbonate | Omeprazole/Sodium Bicarbonate | 40 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 39 | 18 |
| Acarbose | Acarbose | 38 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 38 | 17 |
| Nebivolol Hcl | Nebivolol Hcl | 38 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 37 | 25 |
| Metformin Hcl Er | Metformin Hcl | 34 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 33 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 33 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 32 | 12 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 31 | 17 |
| Meloxicam | Meloxicam, Submicronized | 31 | suppressed |
| Prednisone | Prednisone | 31 | 16 |
| Potassium Chloride | Potassium Chloride | 29 | suppressed |
| Rivastigmine | Rivastigmine | 27 | suppressed |
| Dihydroergotamine Mesylate | Dihydroergotamine Mesylate | 26 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 26 | suppressed |
| Sotalol | Sotalol Hcl | 26 | suppressed |
| Alprazolam | Alprazolam | 25 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 25 | suppressed |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 25 | 14 |
| Indomethacin | Indomethacin | 25 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 24 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 24 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 24 | suppressed |
| Terconazole | Terconazole | 24 | suppressed |
| Lisinopril | Lisinopril | 23 | suppressed |
| Olanzapine | Olanzapine | 23 | suppressed |
| Telmisartan | Telmisartan | 23 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 22 | suppressed |
| Comfort Touch Pen Needle | Pen Needle, Diabetic | 22 | suppressed |
| Entecavir | Entecavir | 21 | suppressed |
| Ezetimibe | Ezetimibe | 21 | suppressed |
| Lidocaine Hcl Viscous | Lidocaine Hcl | 21 | 13 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 21 | 19 |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 21 | suppressed |
| Tobramycin | Tobramycin | 21 | 16 |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 20 | suppressed |
| Latanoprost | Latanoprost | 20 | suppressed |
| Linzess | Linaclotide | 20 | suppressed |
| Ofloxacin | Ofloxacin | 20 | suppressed |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 20 | suppressed |
| Proctozone-Hc | Hydrocortisone | 20 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 20 | suppressed |
| Ciclopirox | Ciclopirox Olamine | 19 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 19 | suppressed |
| Levetiracetam | Levetiracetam | 19 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 19 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 19 | suppressed |
| Tavaborole | Tavaborole | 19 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 18 | 18 |
| Tobramycin-Dexamethasone | Tobramycin/Dexamethasone | 18 | suppressed |
| Unifine Pentips Plus | Pen Needle, Diabetic | 18 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 17 | suppressed |
| Glipizide Er | Glipizide | 16 | suppressed |
| Methimazole | Methimazole | 16 | suppressed |
| Pregabalin | Pregabalin | 16 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 15 | suppressed |
| Methylprednisolone | Methylprednisolone | 15 | suppressed |
| Ranolazine Er | Ranolazine | 15 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 15 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 15 | suppressed |
| Calcitriol | Calcitriol | 14 | suppressed |
| Chlorzoxazone | Chlorzoxazone | 14 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 14 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 14 | suppressed |
| Ozempic | Semaglutide | 14 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 14 | suppressed |
| Risperidone | Risperidone | 14 | suppressed |
| Acyclovir | Acyclovir | 13 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 13 | suppressed |
| Desoximetasone | Desoximetasone | 13 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 13 | suppressed |
| Febuxostat | Febuxostat | 13 | suppressed |
| Neomycin-Polymyxin-Hydrocort | Neomycin/Polymyxin B/Hydrocort | 13 | suppressed |
| Tobradex | Tobramycin/Dexamethasone | 13 | suppressed |
| Tobradex St | Tobramycin/Dexamethasone | 13 | suppressed |
| Uloric | Febuxostat | 13 | suppressed |
| Alcohol Swab | Alcohol Antiseptic Pads | 12 | suppressed |
| Carvedilol | Carvedilol | 12 | suppressed |
| Diazepam | Diazepam | 12 | suppressed |
| Lorazepam | Lorazepam | 12 | suppressed |
| Repaglinide | Repaglinide | 12 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 12 | suppressed |
| Sucralfate | Sucralfate | 12 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 12 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 12 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 11 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 11 | suppressed |
| Jardiance | Empagliflozin | 11 | suppressed |
| Prolia | Denosumab | 11 | suppressed |
| Sodium Chloride | Sodium Chloride Irrig Solution | 11 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $807.09 · 29 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, BEXSERO, BREZTRI, FARXIGA, FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE, FLUZONE HIGH-DOSE, FLUZONE QUADRIVALENT NORTHERN HEMISPHERE, JARDIANCE, Kerendia, OTEZLA, REPATHA, TRELEGY ELLIPTA, VOQUEZNA, ZENPEP, ZORYVE | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Aimmune Therapeutics, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error